Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of Oral VRB-103 Alone or With Oral Ecnoglutide in Obesity or Overweight
NCT07628127Phase 1Recruiting
- Start
- Jul 2026
- Primary completion
- Mar 2028
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VRB103 in obesity and Overweight (3 arms). Primary endpoints: Number of Participants with Treatment-emergent Adverse Events and Serious Adverse Events at Week 20, Number of Participants with Adverse Events of Special Interest at Week 20 and 2 more. Started Jul 2026; status: recruiting.
02
Drugs
VRB103
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT07628127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07628127.